Americredit Second Quarter Earnings Fall
Dendreon Corp (DNDN ) says that preliminary analysis from Phase III trial of Provenge, a vaccine for treatment of prostate cancer, was inconclusive. It continues ongoing Provenge Phase III trials.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.